? 2022 Association Mieux Prescrire. All rights reserved.NOTHING NEW The only available comparative trial of crizanlizumab (versus placebo) in patients with sickle-cell disease and vaso-occlusive crises failed to provide robust evidence that crizanlizumab tangibly reduces the frequency of vaso-occlusive crises. Nor did it show a reduction in the most serious complications of vaso-occlusive crises. Crizanlizumab appears to mainly carry a risk of gastrointestinal and musculoskeletal disorders, and infusion-related reactions. The risk of haemostatic disorders will need to be monitored. In practice, as of late 2021, the treatments of choice for preventing vaso-occlusive crises due to sickle-cell disease remain hydroxycarbamide, or repeated blood transfusions or exchange transfusions when hydroxycarbamide cannot be used or is insufficiently effective.
展开▼
